Development of Peptide-Based Vaccines for Cancer

被引：83

作者：

Abd-Aziz, Noraini ^{[1
]}

Poh, Chit Laa ^{[1
]}

机构：

[1] Sunway Univ, Ctr Virus & Vaccine Res CVVR, Sch Med & Life Sci, Subang Jaya 47500, Selangor, Malaysia

来源：

JOURNAL OF ONCOLOGY | 2022年 / 2022卷

关键词：

T-CELL RESPONSES; RANDOMIZED CONTROLLED-TRIAL; LOW-DOSE CYCLOPHOSPHAMIDE; COLONY-STIMULATING FACTOR; IMMUNE-RESPONSE; ANTIGEN PRESENTATION; CHECKPOINT BLOCKADE; CATIONIC LIPOSOMES; PROSTATE-CANCER; DENDRITIC CELLS;

D O I：

10.1155/2022/9749363

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Peptides cancer vaccines are designed based on the epitope peptides that can elicit humoral and cellular immune responses targeting tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). In order to develop a clinically safe and more effective vaccine for the future, several issues need to be addressed, and these include the selection of optimal antigen targets, adjuvants, and immunization regimens. Another emerging approach involves the use of personalized peptide-based vaccines based on neoantigens to enhance antitumor response. Rationally designed combinatorial therapy is currently being investigated with chemotherapeutic drugs or immune checkpoint inhibitor therapies to improve the efficacy. This review discusses an overview of the development of peptide-based vaccines, the role of adjuvants, and the delivery systems for peptide vaccines as well as combinatorial therapy as potential anticancer strategies.

引用

页数：17

共 152 条

[91]

2-H

[92] Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial [J].

Noguchi, Masanori ;

Arai, Gaku ;

Egawa, Shin ;

Ohyama, Chikara ;

Naito, Seiji ;

Matsumoto, Kazumasa ;

Uemura, Hirotsugu ;

Nakagawa, Masayuki ;

Nasu, Yasutomo ;

Eto, Masatoshi ;

Suekane, Shigetaka ;

Sasada, Tetsuro ;

Shichijo, Shigeki ;

Yamada, Akira ;

Kakuma, Tatsuyuki ;

Itoh, Kyogo .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (05) :847-857

[93]

Nowak AK, 2002, CANCER RES, V62, P2353

[94] High Therapeutic Efficacy of a New Survivin LSP-Cancer Vaccine Containing CD4+ and CD8+ T-Cell Epitopes [J].

Onodi, Fanny ;

Maherzi-Mechalikh, Chahrazed ;

Mougel, Alice ;

Ben Hamouda, Nadine ;

Taboas, Charlotte ;

Gueugnon, Fabien ;

Tran, Thi ;

Nozach, Herve ;

Marcon, Elodie ;

Gey, Alain ;

Terme, Magali ;

Bouzidi, Ahmed ;

Maillere, Bernard ;

Kerzerho, Jerome ;

Tartour, Eric ;

Tanchot, Corinne .

FRONTIERS IN ONCOLOGY, 2018, 8

[95] A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer [J].

Ott, Patrick A. ;

Hu-Lieskovan, Siwen ;

Chmielowski, Bartosz ;

Govindan, Ramaswamy ;

Naing, Aung ;

Bhardwaj, Nina ;

Margolin, Kim ;

Awad, Mark M. ;

Hellmann, Matthew D. ;

Lin, Jessica J. ;

Friedlander, Terence ;

Bushway, Meghan E. ;

Balogh, Kristen N. ;

Sciuto, Tracey E. ;

Kohler, Victoria ;

Turnbull, Samantha J. ;

Besada, Rana ;

Curran, Riley R. ;

Trapp, Benjamin ;

Scherer, Julian ;

Poran, Asaf ;

Harjanto, Dewi ;

Barthelme, Dominik ;

Ting, Ying Sonia ;

Dong, Jesse Z. ;

Ware, Yvonne ;

Huang, Yuting ;

Huang, Zhengping ;

Wanamaker, Amy ;

Cleary, Lisa D. ;

Moles, Melissa A. ;

Manson, Kelledy ;

Greshock, Joel ;

Khondker, Zakaria S. ;

Fritsch, Ed ;

Rooney, Michael S. ;

DeMario, Mark ;

Gaynor, Richard B. ;

Srinivasan, Lakshmi .

CELL, 2020, 183 (02) :347-+

[96] An immunogenic personal neoantigen vaccine for patients with melanoma [J].

Ott, Patrick A. ;

Hu, Zhuting ;

Keskin, Derin B. ;

Shukla, Sachet A. ;

Sun, Jing ;

Bozym, David J. ;

Zhang, Wandi ;

Luoma, Adrienne ;

Giobbie-Hurder, Anita ;

Peter, Lauren ;

Chen, Christina ;

Olive, Oriol ;

Carter, Todd A. ;

Li, Shuqiang ;

Lieb, David J. ;

Eisenhaure, Thomas ;

Gjini, Evisa ;

Stevens, Jonathan ;

Lane, William J. ;

Javeri, Indu ;

Nellaiappan, Kaliappanadar ;

Salazar, Andres M. ;

Daley, Heather ;

Seaman, Michael ;

Buchbinder, Elizabeth I. ;

Yoon, Charles H. ;

Harden, Maegan ;

Lennon, Niall ;

Gabriel, Stacey ;

Rodig, Scott J. ;

Barouch, Dan H. ;

Aster, Jon C. ;

Getz, Gad ;

Wucherpfennig, Kai ;

Neuberg, Donna ;

Ritz, Jerome ;

Lander, Eric S. ;

Fritsch, Edward F. ;

Hacohen, Nir ;

Wu, Catherine J. .

NATURE, 2017, 547 (7662) :217-+

[97] Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant [J].

Overwijk, Willem W. .

CURRENT OPINION IN IMMUNOLOGY, 2017, 47 :103-109

[98]

Parkhurst MR, 1998, CANCER RES, V58, P4895

[99] Cancer Vaccines, Adjuvants, and Delivery Systems [J].

Paston, Samantha J. ;

Brentville, Victoria A. ;

Symonds, Peter ;

Durrant, Lindy G. .

FRONTIERS IN IMMUNOLOGY, 2021, 12

[100] Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients [J].

Petricevic, Branka ;

Laengle, Johannes ;

Singer, Josef ;

Sachet, Monika ;

Fazekas, Judit ;

Steger, Guenther ;

Bartsch, Rupert ;

Jensen-Jarolim, Erika ;

Bergmann, Michael .

JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11

← 5 6 7 8 9 10 11 12 13 14 →